Psychoactive Drugs Induce the SOS Response and Shiga Toxin Production in Escherichia coli. 2021

John K Crane, and Mashal Salehi, and Cassandra L Alvarado
Department of Medicine, Division of Infectious Diseases, University at Buffalo, Buffalo, NY 14221, USA.

Several classes of non-antibiotic drugs, including psychoactive drugs, proton-pump inhibitors (PPIs), non-steroidal anti-inflammatory drugs (NSAIDs), and others, appear to have strong antimicrobial properties. We considered whether psychoactive drugs induce the SOS response in E. coli bacteria and, consequently, induce Shiga toxins in Shiga-toxigenic E. coli (STEC). We measured the induction of an SOS response using a recA-lacZ E. coli reporter strain, as RecA is an early, reliable, and quantifiable marker for activation of the SOS stress response pathway. We also measured the production and release of Shiga toxin 2 (Stx2) from a classic E. coli O157:H7 strain, derived from a food-borne outbreak due to spinach. Some, but not all, serotonin selective reuptake inhibitors (SSRIs) and antipsychotic drugs induced an SOS response. The use of SSRIs is widespread and increasing; thus, the use of these antidepressants could account for some cases of hemolytic-uremic syndrome due to STEC and is not attributable to antibiotic administration. SSRIs could have detrimental effects on the normal intestinal microbiome in humans. In addition, as SSRIs are resistant to environmental breakdown, they could have effects on microbial communities, including aquatic ecosystems, long after they have left the human body.

UI MeSH Term Description Entries
D001616 beta-Galactosidase A group of enzymes that catalyzes the hydrolysis of terminal, non-reducing beta-D-galactose residues in beta-galactosides. Deficiency of beta-Galactosidase A1 may cause GANGLIOSIDOSIS, GM1. Lactases,Dairyaid,Lactaid,Lactogest,Lactrase,beta-D-Galactosidase,beta-Galactosidase A1,beta-Galactosidase A2,beta-Galactosidase A3,beta-Galactosidases,lac Z Protein,Protein, lac Z,beta D Galactosidase,beta Galactosidase,beta Galactosidase A1,beta Galactosidase A2,beta Galactosidase A3,beta Galactosidases
D013014 SOS Response, Genetics An error-prone mechanism or set of functions for repairing damaged microbial DNA. SOS functions (a concept reputedly derived from the SOS of the international distress signal) are involved in DNA repair and mutagenesis, in cell division inhibition, in recovery of normal physiological conditions after DNA repair, and possibly in cell death when DNA damage is extensive. SOS Response (Genetics),SOS Box,SOS Function,SOS Induction,SOS Region,SOS Repair,SOS Response,SOS System,Box, SOS,Function, SOS,Functions, SOS,Genetics SOS Response,Genetics SOS Responses,Induction, SOS,Inductions, SOS,Region, SOS,Regions, SOS,Repair, SOS,Repairs, SOS,Response, Genetics SOS,Response, SOS,Response, SOS (Genetics),Responses, Genetics SOS,Responses, SOS,Responses, SOS (Genetics),SOS Functions,SOS Inductions,SOS Regions,SOS Repairs,SOS Responses,SOS Responses (Genetics),SOS Responses, Genetics,SOS Systems,System, SOS,Systems, SOS
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D017367 Selective Serotonin Reuptake Inhibitors Compounds that specifically inhibit the reuptake of serotonin in the brain. 5-HT Uptake Inhibitor,5-HT Uptake Inhibitors,5-Hydroxytryptamine Uptake Inhibitor,5-Hydroxytryptamine Uptake Inhibitors,SSRIs,Selective Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitors,Serotonin Uptake Inhibitor,Serotonin Uptake Inhibitors,Inhibitors, 5-HT Uptake,Inhibitors, 5-Hydroxytryptamine Uptake,Inhibitors, Serotonin Reuptake,Inhibitors, Serotonin Uptake,Reuptake Inhibitors, Serotonin,Uptake Inhibitors, 5-HT,Uptake Inhibitors, 5-Hydroxytryptamine,Uptake Inhibitors, Serotonin,Inhibitor, 5-HT Uptake,Inhibitor, 5-Hydroxytryptamine Uptake,Inhibitor, Serotonin Reuptake,Inhibitor, Serotonin Uptake,Reuptake Inhibitor, Serotonin,Uptake Inhibitor, 5-HT,Uptake Inhibitor, 5-Hydroxytryptamine,Uptake Inhibitor, Serotonin
D054323 Shiga-Toxigenic Escherichia coli Strains of ESCHERICHIA COLI with the ability to produce at least one or more of at least two antigenically distinct, usually bacteriophage-mediated cytotoxins: SHIGA TOXIN 1 and SHIGA TOXIN 2. These bacteria can cause severe disease in humans including bloody DIARRHEA and HEMOLYTIC UREMIC SYNDROME. E coli, Verotoxigenic,Escherichia coli, Verotoxigenic,STEC,Verotoxigenic Escherichia coli,Shiga Toxigenic E. coli,Shiga Toxigenic Escherichia coli,Shiga Toxin-Producing Escherichia coli,VTEC,Vero Cytotoxin-Producing Escherichia coli,Verotoxigenic E. coli,Verotoxin-Producing Escherichia coli
D022641 Shiga Toxin 2 A toxin produced by certain pathogenic strains of ESCHERICHIA COLI such as ESCHERICHIA COLI O157. It shares 50-60% homology with SHIGA TOXIN and SHIGA TOXIN 1. SLT-II,SLTII,Shiga Like Toxin II,Shiga Toxin 2, Escherichia coli,Shiga-Like Toxin II,Stx2 protein,VT2 Cytotoxin,Vero Cytotoxin VT2,Verotoxin 2,Cytotoxin, VT2,SLT II

Related Publications

John K Crane, and Mashal Salehi, and Cassandra L Alvarado
December 2019, Scientific reports,
John K Crane, and Mashal Salehi, and Cassandra L Alvarado
January 2000, Emerging infectious diseases,
John K Crane, and Mashal Salehi, and Cassandra L Alvarado
March 2001, Infection and immunity,
John K Crane, and Mashal Salehi, and Cassandra L Alvarado
January 1989, Journal of bacteriology,
John K Crane, and Mashal Salehi, and Cassandra L Alvarado
August 2007, Antimicrobial agents and chemotherapy,
John K Crane, and Mashal Salehi, and Cassandra L Alvarado
August 1986, The Journal of infectious diseases,
John K Crane, and Mashal Salehi, and Cassandra L Alvarado
August 2000, Journal of natural toxins,
John K Crane, and Mashal Salehi, and Cassandra L Alvarado
January 2001, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
John K Crane, and Mashal Salehi, and Cassandra L Alvarado
March 2021, Microbial pathogenesis,
John K Crane, and Mashal Salehi, and Cassandra L Alvarado
January 2015, Foodborne pathogens and disease,
Copied contents to your clipboard!